The U.S. Supreme Court on Thursday ruled against Amgen Inc in its bid to revive patents on its cholesterol-lowering drug Repatha in a legal clash with French rival Sanofi SA .
The 9-0 ruling upheld a lower court's decision that had invalidated Amgen's patents on the grounds that the Thousand Oaks, California-based drugmaker had failed to provide a roadmap for recreating, or "enabling," the full scope of its claimed innovation.
In 2014, Amgen sued Sanofi and Regeneron for patent infringement over their rival drug Praluent, which works by a similar mechanism as Repatha. Both drugs use laboratory-made antibodies to block a protein called PCSK9 that inhibits the removal of bad cholesterol from the blood, but they achieve this result through different chemical combinations.
An Amgen spokesperson expressed disappointment with the court's ruling and said the company "will continue to fight for patent laws and policies" that protect innovation.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Sanofi Wins Supreme Court Patent Dispute With AmgenThe Supreme Court said Amgen patents relating to its cholesterol drug Repatha shouldn’t have been granted by the patent office, handing a victory to rival pharmaceutical firm Sanofi
Read more »
Abortion pill case moves to appeals court, on track for Supreme CourtA federal appeals court in New Orleans hears arguments Wednesday on whether a drug used in the most common method of abortion was properly approved by a government agency more than two decades ago
Read more »
Abortion pill case moves to appeals court, on track for Supreme CourtA federal appeals court in New Orleans hears arguments Wednesday on whether a drug used in the most common method of abortion was properly approved by a government agency more than two decades ago.
Read more »
Abortion pill case moves to appeals court, on track for Supreme CourtAt issue are the FDA’s initial approval of mifepristone in 2000, and FDA actions making the drug more accessible in later years.
Read more »
Mifepristone abortion pill case moves to appeals court, on track for Supreme CourtA federal appeals court in New Orleans hears arguments Wednesday on whether a drug used in the most common method of abortion was properly approved by the FDA in 2000.
Read more »
Abortion pill case moves to appeals court, on track for Supreme CourtAt issue are the FDA’s initial approval of mifepristone in 2000, and FDA actions making the drug more accessible in later years.
Read more »